Patents by Inventor Ronald Bradley DeMattos

Ronald Bradley DeMattos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20220235122
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (A?), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 11312763
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20210371509
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 2, 2021
    Inventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 11078261
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: August 3, 2021
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20200262902
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 20, 2020
    Inventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 10647759
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 12, 2020
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20190382471
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 19, 2019
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Combination Therapy
    Publication number: 20190046536
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-N3pGlu Abeta antibody selected from the group consisting of hE8L, Antibody I, and Antibody II.
    Type: Application
    Filed: March 8, 2017
    Publication date: February 14, 2019
    Inventors: Ronald Bradley DeMattos, Dustin James Mergott, John Randall Sims, II
  • COMBINATION THERAPY
    Publication number: 20190038613
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r, 1?R,4R)-4-methoxy-5?-methyl-6?-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3?H-dispiro[cyclohexane-1,2?-indene-1?,2?-imidazol]-4?-amine, or a pharmaceutically acceptable salt thereof (including the camsylate salt thereof); in combination with an effective amount of an anti-N3pGlu Abeta antibody.
    Type: Application
    Filed: March 10, 2017
    Publication date: February 7, 2019
    Inventors: Ronald Bradley DeMattos, Patrick Cornelius May, John Randall Sims, II
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20180305444
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 25, 2018
    Inventors: Ronald Bradley DEMATTOS, Jirong LU, Ying Tang
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 9944696
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: April 17, 2018
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley DeMattos, Jirong Lu, Ying Tang
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20170204171
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Application
    Filed: January 10, 2017
    Publication date: July 20, 2017
    Applicant: Eli Lilly and Company
    Inventors: Ronald Bradley DeMattos, Jirong LU, Ying Tang
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 8961972
    Abstract: The present invention provides anti-N3pGlu A? antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu A? antibodies or antigen-binding fragment thereof for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Jirong Lu, Ying Tang, Ronald Bradley Demattos
  • Anti-N3PGLU amyloid beta peptide antibodies and uses thereof
    Patent number: 8679498
    Abstract: The present invention provides anti-N3pGlu A? antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu A? antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jirong Lu, Ying Tang, Ronald Bradley Demattos
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20140065138
    Abstract: The present invention provides anti-N3pGlu A? antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu A? antibodies or antigen-binding fragment thereof for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 27, 2013
    Publication date: March 6, 2014
    Applicant: Eli Lilly and Company
    Inventors: Jirong LU, Ying TANG, Ronald Bradley DEMATTOS
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20130142806
    Abstract: The present invention provides anti-N3pGlu A? antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu A? antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease.
    Type: Application
    Filed: August 9, 2011
    Publication date: June 6, 2013
    Applicant: Eli Lilly and Company
    Inventors: Jirong Lu, Ying Tang, Ronald Bradley Demattos
  • PEGylated A? fab
    Patent number: 8066999
    Abstract: A method to treat conditions associated with A? peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human A? peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: November 29, 2011
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley DeMattos, Jirong Lu
  • PEGYLATED ABETA FAB
    Publication number: 20100015155
    Abstract: A method to treat conditions associated with A? peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human A? peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.
    Type: Application
    Filed: January 9, 2008
    Publication date: January 21, 2010
    Inventors: Kelly Renee Bales, Thomas Frank Bumol, Chi-Kin Chow, Ronald Bradley Demattos, Ryan John Hansen, Uma Kuchibhotla, Jirong Lu, Peter Colon McDonnell